Search

Your search keyword '"Psychedelic"' showing total 40 results

Search Constraints

Start Over You searched for: Descriptor "Psychedelic" Remove constraint Descriptor: "Psychedelic" Journal frontiers in psychiatry Remove constraint Journal: frontiers in psychiatry
40 results on '"Psychedelic"'

Search Results

1. Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use.

2. Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use

3. Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.

4. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

5. Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension

6. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

7. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

8. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

9. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

10. Manic episode following psilocybin use in a man with bipolar II disorder: a case report.

11. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.

13. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

14. Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the 'high-risk' addiction patient

15. Manic episode following psilocybin use in a man with bipolar II disorder: a case report

16. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive- compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.

17. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

18. Classic psychedelics do not affect T cell and monocyte immune responses.

19. Classic psychedelics do not affect T cell and monocyte immune responses

20. MDMA for the treatment of misophonia, a proposal.

21. MDMA for the treatment of misophonia, a proposal

22. Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches.

23. Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.

24. Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches

25. Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity

26. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

27. Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.

29. A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development

30. Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research

31. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey

32. Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research.

33. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.

34. Psychedelics and Other Psychoplastogens for Treating Mental Illness.

35. Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

36. Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study.

39. Psychedelics and Other Psychoplastogens for Treating Mental Illness

40. Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes

Catalog

Books, media, physical & digital resources